Halozyme Therapeutics revenue and financials

HALO · NASDAQ · USD

$109.72+1.30%+$1.41

Close · October 6, 2026

In the fiscal year ended December 2025, Halozyme Therapeutics reported revenue of $1.4B (+37.55% year over year). Net income was $316.89M, a net margin of 22.7%.

Annual revenue · 2025: $1.4B

$146.69M2016
$316.61M2017
$151.86M2018
$195.99M2019
$267.59M2020
$443.31M2021
$660.12M2022
$829.25M2023
$1.02B2024
$1.4B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +37.55%; 2025 vs 2024
Net income growth: −28.64%; 2025 vs 2024
Net margin: 22.7%; 2024: 43.7%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	1,397	1,015	829	660	443	268	196	152	317	147
Cost of revenue	229	159	192	139	81.4	43.4	45.5	10.1	31.2	33.2
Gross profit	1,086	777	561	454	326	—	—	—	—	—
Selling, general and administrative	193	154	149	122	50.3	—	—	—	—	—
Research and development	81.5	79.0	76.4	66.6	35.7	34.2	141	150	151	151
Operating income	469	551	338	268	276	144	-67.6	-69.3	81.0	-83.2
EBIT	816	551	338	289	276	—	—	—	—	—
EBITDA	898	627	417	336	277	—	—	—	—	—
Interest expense	18.1	18.1	18.8	16.9	7.5	20.4	11.6	18.0	22.0	20.0
Pre-tax income	467	557	348	249	249	—	—	—	—	—
Income tax	150	113	66.7	46.8	-154	0.2	-0.0	0.5	-1.4	1.2
Net income	317	444	282	202	403	129	-72.2	-80.3	63.0	-103
Net income to common shareholders	317	444	282	202	403	—	—	—	—	—
Basic EPS	2.64	3.50	2.13	1.48	2.86	0.95	-0.50	-0.56	0.46	-0.81
Diluted EPS	2.56	3.43	2.10	1.44	2.74	0.91	-0.50	-0.56	0.45	-0.81
Average shares (basic)	120	127	132	137	141	—	—	—	—	—
Average shares (diluted)	124	129	134	141	147	141	144	144	139	128